Effect of infliximab on inflammatory bowel disease with Takayasu arteritis: Case series and review of the literature

被引：11

作者：

Minami N. ^{[1
]}

Nakase H. ^{[1
]}

Yoshino T. ^{[1
]}

Yamada S. ^{[1
]}

Toyonaga T. ^{[2
]}

Honzawa Y. ^{[1
]}

Matsuura M. ^{[1
]}

Chiba T. ^{[1
]}

机构：

[1] Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Shogoin, Sakyo-ku, Kyoto 606-8507

[2] Third Department of Internal Medicine, Kansai Medical University, Hirakata

来源：

Clinical Journal of Gastroenterology | 2013年 / 6卷 / 3期

关键词：

Inflammatory bowel disease; Infliximab; Takayasu arteritis; Tumor necrosis factor alpha;

D O I：

10.1007/s12328-013-0387-9

中图分类号：

学科分类号：

摘要：

Takayasu arteritis (TA) and inflammatory bowel disease (IBD) are chronic inflammatory disorders. The mechanisms underlying these diseases are not precisely known, but tumor necrosis factor alpha (TNF-α) is considered to have an important role in the pathophysiology of both TA and IBD. Simultaneous occurrence of both TA and IBD is rare. Our first case was a 42-year-old woman with TA and inflammatory bowel disease unclassified. The patient was refractory to treatment with an immunomodulator, and infliximab (IFX) was started. After starting IFX, clinical remission was achieved and maintained for 2 years. The second case was a 34-year-old woman with TA accompanied by Crohn's disease. Because her abdominal symptoms relapsed despite treatment with an immunomodulator, IFX was started. Both diseases were well controlled for 2 years by scheduled maintenance therapy with IFX. Relapse of the TA required increased doses of IFX at shorter intervals, which relieved her symptoms. Overall, we identified nine cases for which IFX was effective, including our 2 cases. They may demonstrate the efficacy of IFX for IBD with TA and emphasize the role of TNF-α in the pathophysiology. © 2013 Springer Japan.

引用

页码：226 / 230

页数：4

共 16 条

[1] Kerr G.S., Hallahan C.W., Giordano J., Leavitt R.Y., Fauci A.S., Rottem M., Et al., Takayasu arteritis, Ann Intern Med, 120, 11, pp. 919-929, (1994)
[2] Johnston S.L., Lock R.J., Gompels M.M., Takayasu arteritis: A review, J Clin Pathol, 55, 7, pp. 481-486, (2002)
[3] Kusunoki R., Ishihara S., Sato M., Sumita Y., Mishima Y., Okada M., Et al., Rare case of Takayasu's arteritis associated with Crohn's disease, Intern Med, 50, 15, pp. 1581-1585, (2011)
[4] Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., Et al., Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, 353, 23, pp. 2462-2476, (2005)
[5] Hoffman G.S., Merkel P.A., Brasington R.D., Lenschow D.J., Liang P., Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis, Arthritis Rheum, 50, 7, pp. 2296-2304, (2004)
[6] Calderon R., Estrada S., Ramirez De La Piscina P., Salvador M., Zabaleta S., Enciso C., Et al., Infliximab in a patient with refractory ileocolic Crohn's disease and Takayasu arteritis, Rev Esp Enferm Dig, 102, 2, pp. 145-146, (2010)
[7] Gecse K., Ruzsa Z., Nagy F., Wittmann T., Molnar T., Successful infliximab treatment in a patient with Takayasu arteritis associated with ulcerative colitis or migration does not override genetics, Inflamm Bowel Dis, 17, 7, (2011)
[8] Kellermayer R., Jain A.K., Ferry G., Deguzman M.M., Guillerman R.P., Clinical challenges and images in GI. Aortitis as a rare complication of Crohn's disease, Gastroenterology, 134, 3, (2008)
[9] Judah J.R., Hammond C.J., Polyak S.F., Drane W.E., Valentine J.F., The coexistence of Crohn's disease and Takayasu arteritis: Diagnosis and treatment of combined disease in three patients, Pract Gastroenterol, 3, pp. 50-58, (2009)
[10] Ratuapli S., Mazlumzadeh M., Gurudu S., Money S., Heigh R., Coexisting Crohn's disease and Takayasu's arteritis in two patients treated with anti-TNF-α therapies, Case Rep Gastroenterol, 4, 1, pp. 35-40, (2010)

← 1 2 →